(Q73379733)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

main subject

phase I clinical trial

1 reference

1 reference

J P Armand

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

L Seymour

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

T R Evans

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

35 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

S14-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

Mature results from three large controlled studies with raltitrexed ('Tomudex').

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Medical management of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Chemotherapy of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

A review of chemotherapy trials for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900043-X

7 January 2021

10.1016/S0959-8049(99)00043-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645209%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference